NCT02997228 2026-03-18
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
32 trialsNCT05253651 2026-03-16
MOUNTAINEER-03
Seagen Inc.
Phase 3 Recruiting
NCT07284849 2026-03-16
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corporation
Phase 3 Recruiting
NCT00905047 2026-03-13
COLOCROSS
Centre Oscar Lambret
Phase 3 Completed
NCT02647099 2026-03-13
ALASCCA
Karolinska Institutet
Phase 3 Active not recruiting
NCT05239741 2026-03-10
MK-3475-C66
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07152821 2026-03-10
BATTMAN
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT00102011 2026-03-09
00-046
Memorial Sloan Kettering Cancer Center
Phase 3 Completed
NCT04230187 2026-03-05
TRIBE-C
Sun Yat-sen University
Phase 3 Recruiting
NCT05673148 2026-03-04
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT07228832 2026-03-03
HARMONi-GI3
Summit Therapeutics
Phase 3 Recruiting
NCT05863195 2026-03-02
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT06252649 2026-02-27
CodeBreaK 301
Amgen
Phase 3 Recruiting
NCT04428905 2026-02-24
Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer
City of Hope Medical Center
Phase 3 Active not recruiting
NCT02945033 2026-02-18
ASPIK French
University Hospital, Rouen
Phase 3 Recruiting
NCT05171660 2026-02-17
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Active not recruiting
NCT03362177 2026-02-11
RECITE
Amgen
Phase 3 Completed
NCT02956876 2026-02-06
INCISIVE
University Hospital, Rouen
Phase 3 Completed
NCT05198934 2026-02-06
CodeBreak300
Amgen
Phase 3 Active not recruiting
NCT04776148 2026-02-05
MK-7902-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT07389265 2026-02-05
CAPRI-3 GOIM
University of Campania Luigi Vanvitelli
Phase 3 Recruiting
NCT06501482 2026-02-04
IRIMAD
Assistance Publique - Hôpitaux de Paris
Phase 3 Recruiting
NCT04854668 2026-01-30
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Active not recruiting
NCT07222800 2026-01-30
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Pfizer
Phase 3 Recruiting
NCT07362836 2026-01-23
Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)
Fudan University
Phase 3 Not yet recruiting
NCT07361003 2026-01-22
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT04457297 2026-01-21
ALTAIR
National Cancer Center Hospital East
Phase 3 Completed
NCT07340567 2026-01-14
CIRCULATEIII
UNICANCER
Phase 3 Not yet recruiting
NCT07320950 2026-01-06
Neuroprotective Effect of Neurotropin on Chronic OXA-induced Neurotoxicity in Stage II and Stage III CRC Patients
Sun Yat-sen University
Phase 3 Completed
NCT07309289 2025-12-30
NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer
Shanghai Zhongshan Hospital
Phase 3 Recruiting
NCT06791512 2025-12-24
BASKETâ…¢
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Recruiting
NCT03869892 2025-12-22
SOLSTICE
Servier
Phase 3 Active not recruiting